Keyword: Nordic Nanovector
Celgene COO Scott Smith resigns, ex-Kite leaders Belldegrun and Chang form new CAR-T shop, GSK Dermatology exec jumps to Dermavant.
The latest setback marks the end of the line for Luigi Costa, who is stepping down as CEO by “mutual agreement” with the company’s board.
Debiopharm has bought a phase 2 antibody-drug conjugate (ADC) from ImmunoGen to add to its clinical-phase cancer pipeline.
Johnson & Johnson Innovation has led a $25 million Series A in targeted cancer radiotherapeutic startup Fusion Pharmaceuticals.
Nordic Nanovector CEO Luigi Costa has talked up the level of third-party interest in non-Hodgkin lymphoma candidate Betalutin.
Nordic Nanovector has raised $60 million to test its CD37-targeting antibody-radionuclide conjugate in combination with rituximab.
Nordic Nanovector has completed enrollment of the first cohorts of the pre-dosed arms of its non-Hodgkin lymphoma trial.